The multidisciplinary team of experts within the Hematologic Malignancies Program combine exceptional expertise, knowledge and skill with advanced therapies to treat benign and malignant blood disorders in a comprehensive and compassionate environment. Physicians are among the nation’s most experienced will expertise in routine, rare and complex hematologic malignancies; treating advanced blood cancers with clinical trials, immunotherapy and other cellular therapies.
Rutgers Cancer Institute is one of the first programs in the state to offer CAR T-cell therapy. CAR T-cell therapy is currently only offered at centers such as ours that perform stem cell transplants, have specially trained clinicians and healthcare personnel, and are FACT (Foundation for the Accreditation of Cellular Therapy) certified.
The Program’s approach to cancer care offers the full spectrum of therapeutic procedures and advanced treatment options for patients with acute and chronic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, myelodysplasia, myeloproliferative diseases, and other hematologic malignancies. Rutgers Cancer Institute in collaboration with Robert Wood Johnson University Hospital, an RWJBarnabas Health facility, is home to one of only two blood and marrow transplant programs in the state and the only one at an NCI-designated Comprehensive Cancer Center.
As a center of excellence in the caring of patients with multiple myeloma, our providers utilize their exceptional expertise and experience to provide comprehensive, compassionate care for patients with multiple myeloma and related diseases.
To help patients better understand and navigate their disease, our program offers a full line of oncology support services including social workers, oncology nurse navigators, dieticians, support groups, on-site pharmacy, and financial counselors. The Program integrates a spectrum of clinical, basic, and translational research activities, assuring close collaboration between basic scientists and clinicians for the rapid translation of research discoveries to clinical care and to enlist the assistance of basic researchers in solving clinical problems.
Rutgers Cancer Institute is recognized as a Center of Excellence by the Myelodysplastic Syndromes (MDS) Foundation in the research, diagnosis and treatment of MDS disorders.
Neil D. Palmisiano, MD, MS, System Leader for Leukemia, RWJBarnabas Health; Deputy Director of Phase I Therapeutics for Hematologic Malignancies, Co-Medical Director of the Office of Human Research Services, Rutgers Cancer Institute
Ira Braunschweig, MD, Chief, Section of Transplant and Cell Therapy, Rutgers Cancer Institute; Chief of the Transplant and Cell Therapy Service of the RWJBarnabas Health Oncology Service Line; Director for Cell Therapy and Bone Marrow Transplantation at Robert Wood Johnson University Hospital
Matthew Matasar, MD, Chief, Division of Blood Disorders
Hematologist/Oncologists
Ira Braunschweig, MD, Chief, Section of Transplant and Cell Therapy, Rutgers Cancer Institute; Chief of the Transplant and Cell Therapy Service of the RWJBarnabas Health Oncology Service Line; Director for Cell Therapy and Bone Marrow Transplantation at Robert Wood Johnson University Hospital
Andrew M. Evens, DO, MBA, MSc, Associate Director for Clinical Services, Rutgers Cancer Institute; System Director of Medical Oncology and Oncology Lead for Combined Medical Group, RWJBarnabas HealthNeil D. Palmisiano, MD, MS, Deputy Director of Phase I Therapeutics for Hematologic Malignancies, Co-Medical Director of the Office of Human Research Services, Rutgers Cancer Institute; System Leader for Leukemia, RWJBarnabas HealthMatthew Matasar, MD, Chief, Division of Blood Disorders
Amer Assal, MD
Hussam Eltoukhy, MD
Anu Doraiswamy, MD
Vimal Patel, MD
Dale Schaar, MD, PhD
Radiation Oncologist
Rahul R, Parikh, MD, Medical Director, Laurie Proton Therapy Center
Nursing Leadership
Advanced Practice Providers
Nurses and Support Services
